Syndax Pharmaceuticals SNDX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $130.89M-3.0% | $134.93M+15.5% | $116.81M+7.5% | $108.64M-29.5% | $153.99M-0.1% | ||
| $221.17M-14.7% | $259.14M-18.8% | $319.17M-7.9% | $346.6M-3.2% | $358.2M-14.5% | ||
| $120.97M+22.7% | $98.58M+44.6% | $68.18M+59.4% | $42.78M+83.4% | $23.32M+207% | ||
| $110.4M+37.8% | $80.11M+67.9% | $47.73M+110% | $22.73M+352% | $5.03M+1,274% | ||
| $471.18M-10.8% | $528.08M-0.3% | $529.83M-0.3% | $531.68M-3.1% | $548.75M-9.0% | ||
| $177K-2.2% | $181K+41.4% | $128K— | $0— | $0— | ||
| $472.67M-10.8% | $529.71M-4.0% | $551.79M-7.4% | $596.15M-7.0% | $640.71M-11.6% | ||
| $10.84M-34.6% | $16.58M+19.9% | $13.83M-20.3% | $17.35M+72.7% | $10.05M-13.6% | ||
| $350M0.0% | $350M+7.0% | $327.08M— | —— | —— | ||
| $86.17M-28.3% | $120.12M+5.2% | $114.19M+1.1% | $112.99M+19.5% | $94.55M-8.7% | ||
| $344.87M0.0% | $344.96M+7.1% | $322.18M-1.1% | $325.74M-1.6% | $331.1M-0.6% | ||
| $431.05M-7.3% | $465.08M+6.6% | $436.36M-0.5% | $438.73M+3.1% | $425.65M-2.5% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | ||
| -$1.55B-2.8% | -$1.51B-4.7% | -$1.44B-4.4% | -$1.38B-5.5% | -$1.31B-6.9% | ||
| $41.62M-35.6% | $64.63M-44.0% | $115.43M-26.7% | $157.42M-26.8% | $215.06M-25.4% | ||
| $472.67M-10.8% | $529.71M-4.0% | $551.79M-7.4% | $596.15M-7.0% | $640.71M-11.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Syndax Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Syndax Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.